Latest Hotspot

IASO Bio showcases Updated Long-Term Follow-Up information for BCMA CAR-T FUCASO®

10 October 2023
3 min read

IASO Bio, a biotech corporation specialized in the identification, development, production, and distribution of groundbreaking cell therapies and antibody solutions, along with Innovent Biologics, Inc., a leading global biopharmaceutical enterprise devoted to producing and selling top-notch medicinal treatments for conditions such as cancer, metabolic disorders, autoimmune diseases, ophthalmologic conditions and other significant illnesses, have unveiled revised long-term follow-up statistics derived from a couple of studies conducted on BCMA CAR-T. 

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

These studies focused on the outcomes of the Phase 1b/2 study carried out on patients who had relapsed/refractory multiple myeloma and were undergoing treatment with Equecabtagene Autoleucel.

A model designed to estimate the likelihood of lengthy recovery from thrombocytopenia in patients suffering from relapsed/refractory multiple myeloma after undergoing anti-BCMA CAR-T treatment will be presented at the 2023 International Myeloma Society Annual Meeting in Vienna, taking place from September 27-30.

CT103A, known as Equecabtagene Autoleucel, is a type of chimeric antigen receptor T-cell therapy made entirely of human-made B-cell maturation antigen-targeting single-chain fragment variable antibody. The latest findings showed a long-term follow-up effectiveness, safety, and the continuity of the phase 1b/2 study completed in 14 clinical sites across China.

Patients with RRMM who had received anti-B cell maturation antigen chimeric antigen receptor-T cell therapy commonly face persistent thrombocytopenia, a hematologic toxicity. This presentation showcases a model that was developed to distinguish between patients at high and low risk for prolonged thrombocytopenia.

The model was devised following an analysis of the base-level clinical attributes of the study's participants, including platelets, C reaction protein, plasma cells present in the marrow, and Ferritin, which was found to contribute significantly to thrombocytopenia recovery. Patients who have a model score of more than 5 post-infusion are at a higher risk of prolonged thrombocytopenia.

"Multiple myeloma is a malignant blood disease that's highly prevalent and relapse and resistance are almost always unavoidable after the existing treatment,” Prof. Lugui Qiu, MD, one of the leading investigators from the Chinese Academy of Medical Science Hematology Hospital, said. "It is critical to find ways to ensure longer-lasting treatments. Equecabtagene Autoleucel, a fully human targeted BCMA CAR-T injection, has proven its ability to have long-term effects and generate a prolonged response."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of October 8, 2023, there are 179 investigational drugs for the BCMA target, including 39 indications,166 R&D institutions involved, with related clinical trials reaching 388and as many as 12602 patents.

Equecabtagene Autoleucel represents a significant advancement in the treatment of multiple diseases, particularly in the field of oncology. Its approval in China and global markets, along with its regulatory designations, highlight its potential to improve patient outcomes and address unmet medical needs.

图形用户界面, 文本, 应用程序

描述已自动生成

The "Antidote" Specific to Biological Toxins: Antitoxin
Advanced Tech.
5 min read
The "Antidote" Specific to Biological Toxins: Antitoxin
10 October 2023
Antitoxin is a specific antibody or serum containing this antibody that can neutralize toxins. By using toxoids for immunization, the body can produce corresponding antitoxins to prevent diseases.
Read →
Mabwell Discloses Initial Patient Treatment in Phase Ib/II Study for Nectin-4 Focused ADC coupled with PD-1 Inhibitor
Latest Hotspot
3 min read
Mabwell Discloses Initial Patient Treatment in Phase Ib/II Study for Nectin-4 Focused ADC coupled with PD-1 Inhibitor
10 October 2023
Mabwell announced the initiation of a Phase Ib/II trial with the first patient dosage. The study uses their novel Nectin-4 ADC (9MW2821) in conjunction with a PD-1 inhibitor for advanced or metastatic urothelial carcinoma.
Read →
Analysis on the Clinical Research Progress of Myostatin inhibitors
Analysis on the Clinical Research Progress of Myostatin inhibitors
10 October 2023
Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletalmuscle, was first described in 1997.
Read →
ImmunoGenesis administers first patient in the Phase 1a/1b clinical study of IMGS-001 for advanced solid tumors
Latest Hotspot
3 min read
ImmunoGenesis administers first patient in the Phase 1a/1b clinical study of IMGS-001 for advanced solid tumors
10 October 2023
ImmunoGenesis announced the first patient treatment in their Phase 1a/1b trial using IMGS-001 at The University of Texas MD Anderson Cancer Center.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.